checkpointtx.com
Anti-PD-L1 Research Program | Checkpoint Therapeutics
http://www.checkpointtx.com/pipeline/anti-pd-l1
Investors & Media. SEC Filings & Financials. We licensed the exclusive worldwide rights to anti-PD-L1 antibodies from Dana-Farber in March 2015. We plan to submit an Investigational New Drug application ( IND ) to the FDA during the first half of 2017. New York, NY 10014.
checkpointtx.com
CK-102 PARP Inhibitor Program | Checkpoint Therapeutics
http://www.checkpointtx.com/pipeline/ck-102-parp-inhibitor-program
Investors & Media. SEC Filings & Financials. CK-102 PARP Inhibitor Program. In December 2015, we obtained the exclusive worldwide rights to develop and commercialize CK-102 (formerly CEP-9722) from Teva Pharmaceutical Industries Ltd., through its subsidiary, Cephalon, Inc. CK-102 is an oral, small molecule selective inhibitor of PARP-1 and PARP-2 enzymes in early clinical development for solid tumors. New York, NY 10014.
checkpointtx.com
Anti-GITR mAb Research Program | Checkpoint Therapeutics
http://www.checkpointtx.com/pipeline/anti-gitr
Investors & Media. SEC Filings & Financials. Anti-GITR mAb Research Program. We licensed the exclusive worldwide rights to anti-GITR antibodies from Dana-Farber in March 2015. Currently we are in preclinical development for this program. New York, NY 10014.
checkpointtx.com
Board of Directors | Checkpoint Therapeutics
http://www.checkpointtx.com/about-us/board-of-directors
Investors & Media. SEC Filings & Financials. Michael S. Weiss Chairman of the Board of Directors. Lindsay A. Rosenwald, MD Director. New York, NY 10014.
checkpointtx.com
Business Development | Checkpoint Therapeutics
http://www.checkpointtx.com/business-development
Investors & Media. SEC Filings & Financials. We are committed to strategic growth through targeted product acquisition. The company actively pursues product/program purchase, in-licensing, and co-development opportunities that are aligned with its internal areas of expertise and offer significant value to its pipeline. Elisabeth Leiderman, MD. Checkpoint Therapeutics, Inc. New York, NY 10014. New York, NY 10014.
checkpointtx.com
Sitemap | Checkpoint Therapeutics
http://www.checkpointtx.com/sitemap
Investors & Media. SEC Filings & Financials. Investors & Media. SEC Filings and Financials. New York, NY 10014.
checkpointtx.com
CK-103 BET Inhibitor | Checkpoint Therapeutics
http://www.checkpointtx.com/pipeline/ck-103-bet-inhibitor
Investors & Media. SEC Filings & Financials. In May 2015, we entered into an exclusive license agreement with Jubilant Biosys Limited ( Jubilant ) to develop and commercialize novel compounds that inhibit the BRD4 protein on a worldwide basis. We plan to submit an IND application to the FDA in 2017. New York, NY 10014.
checkpointtx.com
Management Team | Checkpoint Therapeutics
http://www.checkpointtx.com/about-us/management-team
Investors & Media. SEC Filings & Financials. James F. Oliviero, III, CFA President and Chief Executive Officer. Garrett Gray Vice President, Finance and Accounting and Principal Financial Officer. New York, NY 10014.
checkpointtx.com
Disclaimer | Checkpoint Therapeutics
http://www.checkpointtx.com/disclaimer
Investors & Media. SEC Filings & Financials. New York, NY 10014.